Literature DB >> 20651386

Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis.

Ana Claudia Guedes1, Luis Carlos Zeferino, Kari Juhani Syrjänen, Sylvia Michelina Fernandes Brenna.   

Abstract

AIM: To compare two management strategies for cervical intraepithelial neoplasia (CIN) 2, and evaluate reproducibility of the diagnosis. PATIENTS AND METHODS: Ninety (90) women with biopsy-proven CIN2 diagnosed through the Brazilian public health service were randomly allocated into two groups: 45 in prospective follow-up without treatment, and 45 for radical loop electrosurgical excision procedure (LLETZ). As in the real-life situation, pathology-reviewed diagnoses and HPV genotypes were not available.
RESULTS: Excision of the lesion proved to be more effective than prospective follow-up in reaching clearance of CIN2 (hazard ratio=3.66; 95% confidence interval 2.02-6.64). However, 44.1% of the lesions regressed without treatment during the 12-month follow-up.
CONCLUSION: CIN2 lesions regress without treatment in one year, although an ablative procedure is more effective. However, excision of CIN2 may lead to additional morbidity and costs, and tailoring the management on an individual basis may result in better outcome. Misclassification of CIN2 is not a negligible problem.

Entities:  

Mesh:

Year:  2010        PMID: 20651386

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study.

Authors:  Evangelos Paraskevaidis; Antonios Athanasiou; Maria Paraskevaidi; Evripidis Bilirakis; Georgios Galazios; Emmanuel Kontomanolis; Konstantinos Dinas; Aristotelis Loufopoulos; Maria Nasioutziki; Ioannis Kalogiannidis; Apostolos Athanasiadis; Alexios Papanikolaou; Anastasia Vatopoulou; Gregorios Grimbizis; Dimitrios Tsolakidis; Alexandros Daponte; George Valasoulis; Stella Gritzeli; Georgios Michail; Georgios Adonakis; Minas Paschopoulos; Orestis Tsonis; Maria-Eugenia Anaforidou; Anna Batistatou; Maria Kyrgiou
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.

Authors:  Warner K Huh; Erin Williams; Joice Huang; Tommy Bramley; Nick Poulios
Journal:  Appl Health Econ Health Policy       Date:  2015-02       Impact factor: 2.561

3.  Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.

Authors:  Themba G Ginindza; Benn Sartorius
Journal:  BMC Cancer       Date:  2018-06-07       Impact factor: 4.430

Review 4.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.

Authors:  Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala
Journal:  BMJ       Date:  2018-02-27

5.  Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.

Authors:  Anastasios Skroumpelos; Theodoros Agorastos; Theodoros Constantinidis; Kimon Chatzistamatiou; John Kyriopoulos
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.